{"Clinical Trial ID": "NCT00821964", "Intervention": ["INTERVENTION 1:", "Treatment (biological therapy, chemo)", "Patients receive Abraxane IV for 30 minutes on days 1, 8 and 15 and apply topical imiquimod to QD skin lesions on days 1-4, 8-11, 15-18 and 22-25. Treatment is repeated every 28 days for up to 3 cycles in the absence of disease progression or unacceptable toxicity.", "imiquimod: According to news", "Abraxane: under IV", "Analysis of laboratory biomarkers: related studies", "RNA analysis: related studies", "Immunoenzyme technique: related studies"], "Eligibility": ["Incorporation criteria:", "Patients with advanced refractory breast cancer", "A progressive or relapsed disease after standard chemotherapy and/or surgery, and/or radiotherapy", "Patients should have measurable (bidimensional) chest wall disease and/or metastatic skin lesions.", "Patients should be at least 7 days after the last chemotherapy and 30 days after local radiation therapy and/or systemic steroids.", "Patients on bisphosphonates, trastuzumab, lapatinib and/or hormonal therapy are eligible", "Number of white blood cells >= 1000/ul", "Absolute number of neutrophils (ANC) >= 1200/ul", "Blisters > 75 000/ul", "Serum creatinine level = < 2.0 mg/dL, creatinine clearance > 60 ml/min", "Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) < 2 X upper normal limit (ULN)", "Total bilirubin < 2 X ULN", "Patients should have a performance rating (Eastern Cooperative Oncology Group (ECOG) scale) = < 2", "Patients should have recovered from major infections and/or surgical procedures and, in the opinion of the investigator, have no significant concomitant medical disease excluding protocol treatment", "Men and women of childbearing potential should accept the use of contraceptives during the study and for 1 month after discontinuation of imiquimod/Abraxane therapy.", "- Exclusion criteria:", "Patients with a previous allergic reaction to taxanes", "Patients with clinically significant active autoimmune disease requiring active treatment with systemic steroids or other immunomodulators", "Pregnant or lactating women", "Patients with peripheral neuropathy >= Grade 2"], "Results": ["Performance measures:", "Anti-tumour effects of imiquimod assessed by modified World Health Organization (WHO) criteria", "The target lesions will be evaluated according to the following response criteria: complete response (CR), partial response (PR), stable disease (SD) or progressive disease (PD).", "Assessment of target lesions by WHO modified response criteria:", "Complete response (CR): complete clearance (100%) of target injury(s)", "Partial response (PR): 50% decrease in target injury size", "- Disease stable (SD): < 50% decrease in target lesion size", "Progressive (PD): 25% increase in target injury size Overall response rate (ORR) determined at the end of treatment at the end of the study, i.e. one week after Cycle 3, unless the patient was removed from the study.", "Timeline: Baseline, then every 4 weeks to week 24", "Results 1:", "Title of the arm/group: Treatment (biological therapy, chemo)", "Description of the arm/group: Patients receive Abraxane IV for 30 minutes on days 1, 8 and 15 and apply topical imiquimod to QD skin lesions on days 1-4, 8-11, 15-18 and 22-25. Treatment is repeated every 28 days for up to 3 cycles in the absence of disease progression or unacceptable toxicity.", "imiquimod: According to news", "Abraxane: under IV", "Analysis of laboratory biomarkers: related studies", "RNA analysis: related studies", "Immunoenzyme technique: related studies", "Total number of participants analysed: 14", "Type of measure: Number of participants", "Unit of measure: Participants Total assessed in this result Measure: 14 100.0%", "\u2022 Complete response (CR): 5 35.7%", "- Partial response (PR): 5 35.7%", "\u2022 Disease stable (SD): 3 21.4%", "Progressive diseases (PD): 1 7.1 per cent"], "Adverse Events": ["Undesirable Events 1:", "Total: 1/15 (6.67 per cent)", "Pain 1/15 (6.67 per cent)"]}